Blast phase Chronic myeloid leukemia
Also known as: Blast phase chronic myelogenic leukaemia / Blast phase chronic myologenic leukemia / Chronic Myelogenous Leukemia With Crisis of Blast Cells / Chronic Myelogenous Leukemia in Blast Crisis / Blastic Phase Chronic Myelogenous Leukemia / Blast-phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia (CML) in Blast Crisis / Blast phase Chronic myelocytic leukemia / Chronic Myelogenous Leukemia, Blastic Phase / Chronic Myeloid Leukemia, Blast Crisis / Blastic Phase Chronic Myeloid Leukemia / Blast Phase Chronic Myelogenous Leukemia (CML) / Blast phase Chronic myelogenous leukemia / Blastic phase chronic myeloid leukemia (disorder) / Blast cell crisis / Blast crisis (qualifier value) / Blast Crisis / Chronic myeloid leukaemia transformation
Drug | Drug Name | Drug Description |
---|---|---|
DB06616 | Bosutinib | An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. |
DB00987 | Cytarabine | A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia. |
DB01254 | Dasatinib | A tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia. |
DB00619 | Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |
DB08901 | Ponatinib | A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). |